🔴 KLRA is trading 5.8% down today despite announcing positive Phase 3 trial data for its obesity and diabetes drug.

KLRA is trading 5.8% down at $21.96 today, undergoing a pullback. This occurs despite Kailera Therapeutics announcing positive topline data from two Phase 3 clinical trials for its oral GLP-1 receptor agonist, HRS-7535/KAI-7535, in China.

• In obesity/overweight trials, the drug achieved mean weight loss of up to 11.1% at Week 50.
• The drug also met its main goal in Type 2 diabetes trials, reducing HbA1c by 1.50%–1.68%.
• The stock's current decline suggests profit-taking after its post-IPO rally and broader market weakness, overshadowing the positive clinical news.